pharmaphorum1y
Pharnext hit again as rare disease drug flunks phase 3 test
which has lost almost all its value since Pharnext decided to abandon the development of its earlier lead candidate – PXT864 (baclofen and acamprosate) for Alzheimer’s disease – earlier this ...